Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
|Podcasts|July 20, 2020
Speaking of Urology: A HIFU expert discusses his treatment criteria
Author(s)Urology Times staff
In this episode, Samuel J. Peretsman, MD, describes his background and experience with HIFU as a treatment for patients with prostate cancer, and also discusses his treatment criteria for the modality.
Advertisement
Be sure to listen our first episode as well:
Advertisement
Related to this article
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
How PSMA-PET shapes staging and recurrence workup in prostate cancer
3
ESMO 2026: Key presentations across genitourinary oncology
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5